Biotech company Amgen (NASDAQ:AMGN) announced better-than-expected revenue in Q1 CY2026, with sales up 5.8% year on year to ...

Amgen Inc (AMGN) reports a robust 4% growth in product sales, driven by key growth drivers, while navigating patent expirations and increased competition.

Good afternoon, everyone, and welcome to our first quarter of 2026 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Murdo Gordon, Jay ...

Out of 22 S&P 500 healthcare companies that reported results this week, 19 beat earnings expectations and 15 posted year-over ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen today and set a price target of $432.00. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful in ...

Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on Amgen today and set a price target of $307.00. Ahmad covers the Healthcare sector, focusing on stocks such as ACADIA ...

Biotech company Amgen (NASDAQ:AMGN) will be announcing earnings results this Thursday afternoon. Here’s what investors should ...

In its upcoming report, Amgen (AMGN) is predicted by Wall Street analysts to post quarterly earnings of $4.73 per share, reflecting a decline of 3.5% compared to the same period last year. Revenues ...

Amgen shares have risen 6% since the beginning of the year, while the S&P's 500 index has risen slightly more than 5%. In the final minutes of trading on Thursday, shares hit $347.44, a rise of 19% in ...

Fintel reports that on April 21, 2026, Canaccord Genuity initiated coverage of Amgen (NasdaqGS:AMGN) with a Hold ...